Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 76

1.

Metabolic Reprogramming Promotes Myogenesis During Aging.

Belli R, Bonato A, De Angelis L, Mirabilii S, Ricciardi MR, Tafuri A, Molfino A, Leigheb M, Costelli P, Caruso M, Muscaritoli M, Ferraro E.

Front Physiol. 2019 Jul 10;10:897. doi: 10.3389/fphys.2019.00897. eCollection 2019.

2.

Activation of liver X receptor up-regulates the expression of the NKG2D ligands MICA and MICB in multiple myeloma through different molecular mechanisms.

Bilotta MT, Abruzzese MP, Molfetta R, Scarno G, Fionda C, Zingoni A, Soriani A, Garofalo T, Petrucci MT, Ricciardi MR, Paolini R, Santoni A, Cippitelli M.

FASEB J. 2019 Aug;33(8):9489-9504. doi: 10.1096/fj.201900319R. Epub 2019 May 24.

PMID:
31125275
3.

Correction to: One shot NEPA plus dexamethasone to prevent chemotherapy-induced nausea and vomiting (CINV) in sarcoma patients receiving multiple-day chemotherapy.

Badalamenti G, Incorvaia L, Messina C, Musso E, Casarin A, Ricciardi MR, De Luca I, Bazan V, Russo A.

Support Care Cancer. 2019 Sep;27(9):3599. doi: 10.1007/s00520-019-04852-8.

PMID:
31087158
4.

Central nervous system immune reconstitution inflammatory syndrome after autologous stem cell transplantation.

Campagna A, Gianfelici V, Antolino G, Pelliccia S, Galassi G, Piedimonte M, Bianchi MP, Mirabilii S, Ricciardi MR, Tasca G, Iorio R, Conte E, Ferrari A, La Verde G, Tafuri A.

Bone Marrow Transplant. 2019 May 8. doi: 10.1038/s41409-019-0532-2. [Epub ahead of print] No abstract available.

PMID:
31068657
5.

The homeobox transcription factor MEIS2 is a regulator of cancer cell survival and IMiDs activity in Multiple Myeloma: modulation by Bromodomain and Extra-Terminal (BET) protein inhibitors.

Abruzzese MP, Bilotta MT, Fionda C, Zingoni A, Soriani A, Petrucci MT, Ricciardi MR, Molfetta R, Paolini R, Santoni A, Cippitelli M.

Cell Death Dis. 2019 Apr 11;10(4):324. doi: 10.1038/s41419-019-1562-9.

6.

One shot NEPA plus dexamethasone to prevent multiple-day chemotherapy in sarcoma patients.

Badalamenti G, Incorvaia L, Messina C, Musso E, Casarin A, Ricciardi MR, De Luca I, Bazan V, Russo A.

Support Care Cancer. 2019 Sep;27(9):3593-3597. doi: 10.1007/s00520-019-4645-3. Epub 2019 Feb 14. Erratum in: Support Care Cancer. 2019 May 14;:.

7.

A rare BCR-ABL1 transcript in Philadelphia-positive acute myeloid leukemia: case report and literature review.

Piedimonte M, Ottone T, Alfonso V, Ferrari A, Conte E, Divona M, Bianchi MP, Ricciardi MR, Mirabilii S, Licchetta R, Campagna A, Cicconi L, Galassi G, Pelliccia S, Leporace A, Lo Coco F, Tafuri A.

BMC Cancer. 2019 Jan 10;19(1):50. doi: 10.1186/s12885-019-5265-5. Review.

8.

Key Role of the CD56lowCD16low Natural Killer Cell Subset in the Recognition and Killing of Multiple Myeloma Cells.

Vulpis E, Stabile H, Soriani A, Fionda C, Petrucci MT, Mariggio' E, Ricciardi MR, Cippitelli M, Gismondi A, Santoni A, Zingoni A.

Cancers (Basel). 2018 Nov 29;10(12). pii: E473. doi: 10.3390/cancers10120473.

9.

Biological Aspects of mTOR in Leukemia.

Mirabilii S, Ricciardi MR, Piedimonte M, Gianfelici V, Bianchi MP, Tafuri A.

Int J Mol Sci. 2018 Aug 14;19(8). pii: E2396. doi: 10.3390/ijms19082396. Review.

10.

Differential proteomic profile of leukemic CD34+ progenitor cells from chronic myeloid leukemia patients.

Ricciardi MR, Salvestrini V, Licchetta R, Mirabilii S, Forcato M, Gugliotta G, Salati S, Castagnetti F, Rosti G, Breccia M, Alimena G, Manfredini R, Bicciato S, Lemoli RM, Tafuri A.

Oncotarget. 2018 Apr 24;9(31):21758-21769. doi: 10.18632/oncotarget.24938. eCollection 2018 Apr 24.

11.

MICA-129 Dimorphism and Soluble MICA Are Associated With the Progression of Multiple Myeloma.

Zingoni A, Vulpis E, Cecere F, Amendola MG, Fuerst D, Saribekyan T, Achour A, Sandalova T, Nardone I, Peri A, Soriani A, Fionda C, Mariggiò E, Petrucci MT, Ricciardi MR, Mytilineos J, Cippitelli M, Cerboni C, Santoni A.

Front Immunol. 2018 May 1;9:926. doi: 10.3389/fimmu.2018.00926. eCollection 2018.

12.

Drug-Induced Senescent Multiple Myeloma Cells Elicit NK Cell Proliferation by Direct or Exosome-Mediated IL15 Trans-Presentation.

Borrelli C, Ricci B, Vulpis E, Fionda C, Ricciardi MR, Petrucci MT, Masuelli L, Peri A, Cippitelli M, Zingoni A, Santoni A, Soriani A.

Cancer Immunol Res. 2018 Jul;6(7):860-869. doi: 10.1158/2326-6066.CIR-17-0604. Epub 2018 Apr 24.

13.

Preclinical Antileukemia Activity of Tramesan: A Newly Identified Bioactive Fungal Metabolite.

Ricciardi MR, Licchetta R, Mirabilii S, Scarpari M, Parroni A, Fabbri AA, Cescutti P, Reverberi M, Fanelli C, Tafuri A.

Oxid Med Cell Longev. 2017;2017:5061639. doi: 10.1155/2017/5061639. Epub 2017 Nov 15.

14.

Energetic mitochondrial failing in vitiligo and possible rescue by cardiolipin.

Dell'Anna ML, Ottaviani M, Kovacs D, Mirabilii S, Brown DA, Cota C, Migliano E, Bastonini E, Bellei B, Cardinali G, Ricciardi MR, Tafuri A, Picardo M.

Sci Rep. 2017 Oct 20;7(1):13663. doi: 10.1038/s41598-017-13961-5.

15.

Measuring malevolent character: Data using the Swedish version of Jonason's Dark Triad Dirty Dozen.

Garcia D, Rosenberg P, MacDonald S, Räisänen C, Ricciardi MR.

Data Brief. 2017 Aug 31;14:648-652. doi: 10.1016/j.dib.2017.08.020. eCollection 2017 Oct.

16.

Innate immune activating ligand SUMOylation affects tumor cell recognition by NK cells.

Zitti B, Molfetta R, Fionda C, Quatrini L, Stabile H, Lecce M, de Turris V, Ricciardi MR, Petrucci MT, Cippitelli M, Gismondi A, Santoni A, Paolini R.

Sci Rep. 2017 Sep 5;7(1):10445. doi: 10.1038/s41598-017-10403-0.

17.

Tramesan, a novel polysaccharide from Trametes versicolor. Structural characterization and biological effects.

Scarpari M, Reverberi M, Parroni A, Scala V, Fanelli C, Pietricola C, Zjalic S, Maresca V, Tafuri A, Ricciardi MR, Licchetta R, Mirabilii S, Sveronis A, Cescutti P, Rizzo R.

PLoS One. 2017 Aug 22;12(8):e0171412. doi: 10.1371/journal.pone.0171412. eCollection 2017.

18.

Targeting the Akt, GSK-3, Bcl-2 axis in acute myeloid leukemia.

Ricciardi MR, Mirabilii S, Licchetta R, Piedimonte M, Tafuri A.

Adv Biol Regul. 2017 Aug;65:36-58. doi: 10.1016/j.jbior.2017.05.002. Epub 2017 May 19. Review.

PMID:
28549531
19.

Genotoxic stress modulates the release of exosomes from multiple myeloma cells capable of activating NK cell cytokine production: Role of HSP70/TLR2/NF-kB axis.

Vulpis E, Cecere F, Molfetta R, Soriani A, Fionda C, Peruzzi G, Caracciolo G, Palchetti S, Masuelli L, Simonelli L, D'Oro U, Abruzzese MP, Petrucci MT, Ricciardi MR, Paolini R, Cippitelli M, Santoni A, Zingoni A.

Oncoimmunology. 2017 Jan 13;6(3):e1279372. doi: 10.1080/2162402X.2017.1279372. eCollection 2017.

20.

High expression levels of IP10/CXCL10 are associated with modulation of the natural killer cell compartment in multiple myeloma.

Bernardini G, Vulpis E, Bonanni V, Stabile H, Ricciardi MR, Petrucci MT, Gismondi A, Santoni A, Zingoni A.

Leuk Lymphoma. 2017 Oct;58(10):2493-2496. doi: 10.1080/10428194.2017.1295144. Epub 2017 Feb 28. No abstract available.

PMID:
28278706
21.

Work- related Stress, over-nutrition and cognitive disability.

Ippoliti F, Corbosiero P, Canitano N, Massoni F, Ricciardi MR, Ricci L, Archer T, Ricci S.

Clin Ter. 2017 Jan-Feb;168(1):e42-e47. doi: 10.7417/CT.2017.1981. Review.

22.

p38 MAPK differentially controls NK activating ligands at transcriptional and post-transcriptional level on multiple myeloma cells.

Soriani A, Borrelli C, Ricci B, Molfetta R, Zingoni A, Fionda C, Carnevale S, Abruzzese MP, Petrucci MT, Ricciardi MR, La Regina G, Di Cesare E, Lavia P, Silvestri R, Paolini R, Cippitelli M, Santoni A.

Oncoimmunology. 2016 Dec 2;6(1):e1264564. doi: 10.1080/2162402X.2016.1264564. eCollection 2017.

23.

Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay.

Abruzzese MP, Bilotta MT, Fionda C, Zingoni A, Soriani A, Vulpis E, Borrelli C, Zitti B, Petrucci MT, Ricciardi MR, Molfetta R, Paolini R, Santoni A, Cippitelli M.

J Hematol Oncol. 2016 Dec 1;9(1):134.

24.

Erratum: The pan-class I phosphatidyl-inositol-3 kinase inhibitor NVP-BKM120 demonstrates anti-leukemic activity in acute myeloid leukemia.

Allegretti M, Ricciardi MR, Licchetta R, Mirabilii S, Orecchioni S, Reggiani F, Talarico G, Foà R, Bertolini F, Amadori S, Torrisi MR, Tafuri A.

Sci Rep. 2016 Feb 5;6:20743. doi: 10.1038/srep20743. No abstract available.

25.

The pan-class I phosphatidyl-inositol-3 kinase inhibitor NVP-BKM120 demonstrates anti-leukemic activity in acute myeloid leukemia.

Allegretti M, Ricciardi MR, Licchetta R, Mirabilii S, Orecchioni S, Reggiani F, Talarico G, Foà R, Bertolini F, Amadori S, Torrisi MR, Tafuri A.

Sci Rep. 2015 Dec 17;5:18137. doi: 10.1038/srep18137. Erratum in: Sci Rep. 2016;6:20743.

26.

Multiple Myeloma Impairs Bone Marrow Localization of Effector Natural Killer Cells by Altering the Chemokine Microenvironment.

Ponzetta A, Benigni G, Antonangeli F, Sciumè G, Sanseviero E, Zingoni A, Ricciardi MR, Petrucci MT, Santoni A, Bernardini G.

Cancer Res. 2015 Nov 15;75(22):4766-77. doi: 10.1158/0008-5472.CAN-15-1320. Epub 2015 Oct 5.

27.

Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia.

Iacovelli S, Ricciardi MR, Allegretti M, Mirabilii S, Licchetta R, Bergamo P, Rinaldo C, Zeuner A, Foà R, Milella M, McCubrey JA, Martelli AM, Tafuri A.

Oncotarget. 2015 Oct 13;6(31):32089-103. doi: 10.18632/oncotarget.5156.

28.

Targeting the leukemia cell metabolism by the CPT1a inhibition: functional preclinical effects in leukemias.

Ricciardi MR, Mirabilii S, Allegretti M, Licchetta R, Calarco A, Torrisi MR, Foà R, Nicolai R, Peluso G, Tafuri A.

Blood. 2015 Oct 15;126(16):1925-9. doi: 10.1182/blood-2014-12-617498. Epub 2015 Aug 14.

PMID:
26276667
29.

The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma.

Fionda C, Abruzzese MP, Zingoni A, Cecere F, Vulpis E, Peruzzi G, Soriani A, Molfetta R, Paolini R, Ricciardi MR, Petrucci MT, Santoni A, Cippitelli M.

Oncotarget. 2015 Sep 15;6(27):23609-30.

30.

The tissue inhibitor of metalloproteinases 1 increases the clonogenic efficiency of human hematopoietic progenitor cells through CD63/PI3K/Akt signaling.

Rossi L, Forte D, Migliardi G, Salvestrini V, Buzzi M, Ricciardi MR, Licchetta R, Tafuri A, Bicciato S, Cavo M, Catani L, Lemoli RM, Curti A.

Exp Hematol. 2015 Nov;43(11):974-985.e1. doi: 10.1016/j.exphem.2015.07.003. Epub 2015 Jul 23.

PMID:
26213230
31.

Genotoxic Stress Induces Senescence-Associated ADAM10-Dependent Release of NKG2D MIC Ligands in Multiple Myeloma Cells.

Zingoni A, Cecere F, Vulpis E, Fionda C, Molfetta R, Soriani A, Petrucci MT, Ricciardi MR, Fuerst D, Amendola MG, Mytilineos J, Cerboni C, Paolini R, Cippitelli M, Santoni A.

J Immunol. 2015 Jul 15;195(2):736-48. doi: 10.4049/jimmunol.1402643. Epub 2015 Jun 12.

32.

PARP inhibitor ABT-888 affects response of MDA-MB-231 cells to doxorubicin treatment, targeting Snail expression.

Mariano G, Ricciardi MR, Trisciuoglio D, Zampieri M, Ciccarone F, Guastafierro T, Calabrese R, Valentini E, Tafuri A, Del Bufalo D, Caiafa P, Reale A.

Oncotarget. 2015 Jun 20;6(17):15008-21.

33.

Che-1-induced inhibition of mTOR pathway enables stress-induced autophagy.

Desantis A, Bruno T, Catena V, De Nicola F, Goeman F, Iezzi S, Sorino C, Ponzoni M, Bossi G, Federico V, La Rosa F, Ricciardi MR, Lesma E, De Meo PD, Castrignanò T, Petrucci MT, Pisani F, Chesi M, Bergsagel PL, Floridi A, Tonon G, Passananti C, Blandino G, Fanciulli M.

EMBO J. 2015 May 5;34(9):1214-30. doi: 10.15252/embj.201489920. Epub 2015 Mar 14.

34.

Increased chronic lymphocytic leukemia proliferation upon IgM stimulation is sustained by the upregulation of miR-132 and miR-212.

Tavolaro S, Colombo T, Chiaretti S, Peragine N, Fulci V, Ricciardi MR, Messina M, Bonina S, Brugnoletti F, Marinelli M, Di Maio V, Mauro FR, Del Giudice I, Macino G, Foà R, Guarini A.

Genes Chromosomes Cancer. 2015 Apr;54(4):222-34. doi: 10.1002/gcc.22236. Epub 2015 Feb 2.

PMID:
25645730
35.

Aflatoxin control in maize by Trametes versicolor.

Scarpari M, Bello C, Pietricola C, Zaccaria M, Bertocchi L, Angelucci A, Ricciardi MR, Scala V, Parroni A, Fabbri AA, Reverberi M, Zjalic S, Fanelli C.

Toxins (Basel). 2014 Dec 17;6(12):3426-37. doi: 10.3390/toxins6123426.

36.

Reactive oxygen species- and DNA damage response-dependent NK cell activating ligand upregulation occurs at transcriptional levels and requires the transcriptional factor E2F1.

Soriani A, Iannitto ML, Ricci B, Fionda C, Malgarini G, Morrone S, Peruzzi G, Ricciardi MR, Petrucci MT, Cippitelli M, Santoni A.

J Immunol. 2014 Jul 15;193(2):950-60. doi: 10.4049/jimmunol.1400271. Epub 2014 Jun 9.

37.

Neurodegenerative aspects in vulnerability to schizophrenia spectrum disorders.

Archer T, Ricci S, Garcia D, Ricciardi MR.

Neurotox Res. 2014 Nov;26(4):400-13. doi: 10.1007/s12640-014-9473-0. Epub 2014 May 8. Review.

PMID:
24804834
38.

Inhibition of glycogen synthase kinase-3 increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of STAT3.

Fionda C, Malgarini G, Soriani A, Zingoni A, Cecere F, Iannitto ML, Ricciardi MR, Federico V, Petrucci MT, Santoni A, Cippitelli M.

J Immunol. 2013 Jun 15;190(12):6662-72. doi: 10.4049/jimmunol.1201426. Epub 2013 May 17.

39.

IgD cross-linking induces gene expression profiling changes and enhances apoptosis in chronic lymphocytic leukemia cells.

Tavolaro S, Peragine N, Chiaretti S, Ricciardi MR, Raponi S, Messina M, Santangelo S, Marinelli M, Di Maio V, Mauro FR, Del Giudice I, Foà R, Guarini A.

Leuk Res. 2013 Apr;37(4):455-62. doi: 10.1016/j.leukres.2012.12.019. Epub 2013 Jan 19.

PMID:
23337402
40.

Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for "vertical" and "lateral" combination strategies.

Ricciardi MR, Scerpa MC, Bergamo P, Ciuffreda L, Petrucci MT, Chiaretti S, Tavolaro S, Mascolo MG, Abrams SL, Steelman LS, Tsao T, Marchetti A, Konopleva M, Del Bufalo D, Cognetti F, Foà R, Andreeff M, McCubrey JA, Tafuri A, Milella M.

J Mol Med (Berl). 2012 Oct;90(10):1133-44. doi: 10.1007/s00109-012-0886-z. Epub 2012 Mar 8.

PMID:
22399013
41.

The mitogen-activated protein kinase (MAPK) cascade controls phosphatase and tensin homolog (PTEN) expression through multiple mechanisms.

Ciuffreda L, Di Sanza C, Cesta Incani U, Eramo A, Desideri M, Biagioni F, Passeri D, Falcone I, Sette G, Bergamo P, Anichini A, Sabapathy K, McCubrey JA, Ricciardi MR, Tafuri A, Blandino G, Orlandi A, De Maria R, Cognetti F, Del Bufalo D, Milella M.

J Mol Med (Berl). 2012 Jun;90(6):667-79. doi: 10.1007/s00109-011-0844-1. Epub 2012 Jan 4.

PMID:
22215152
42.

A subset of chronic lymphocytic leukemia patients display reduced levels of PARP1 expression coupled with a defective irradiation-induced apoptosis.

Bacalini MG, Tavolaro S, Peragine N, Marinelli M, Santangelo S, Del Giudice I, Mauro FR, Di Maio V, Ricciardi MR, Caiafa P, Chiaretti S, Foà R, Guarini A, Reale A.

Exp Hematol. 2012 Mar;40(3):197-206.e1. doi: 10.1016/j.exphem.2011.11.005. Epub 2011 Nov 23.

PMID:
22120020
43.

MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex.

Konopleva M, Milella M, Ruvolo P, Watts JC, Ricciardi MR, Korchin B, McQueen T, Bornmann W, Tsao T, Bergamo P, Mak DH, Chen W, McCubrey J, Tafuri A, Andreeff M.

Leukemia. 2012 Apr;26(4):778-87. doi: 10.1038/leu.2011.287. Epub 2011 Nov 8.

44.

Purinergic signaling inhibits human acute myeloblastic leukemia cell proliferation, migration, and engraftment in immunodeficient mice.

Salvestrini V, Zini R, Rossi L, Gulinelli S, Manfredini R, Bianchi E, Piacibello W, Caione L, Migliardi G, Ricciardi MR, Tafuri A, Romano M, Salati S, Di Virgilio F, Ferrari S, Baccarani M, Ferrari D, Lemoli RM.

Blood. 2012 Jan 5;119(1):217-26. doi: 10.1182/blood-2011-07-370775. Epub 2011 Nov 3.

PMID:
22053107
45.

Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma.

Moschetta M, Di Pietro G, Ria R, Gnoni A, Mangialardi G, Guarini A, Ditonno P, Musto P, D'Auria F, Ricciardi MR, Dammacco F, Ribatti D, Vacca A.

Eur J Cancer. 2010 Jan;46(2):420-9. doi: 10.1016/j.ejca.2009.10.019. Epub 2009 Nov 13.

PMID:
19914061
46.

Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations.

Ciuffreda L, Del Bufalo D, Desideri M, Di Sanza C, Stoppacciaro A, Ricciardi MR, Chiaretti S, Tavolaro S, Benassi B, Bellacosa A, Foà R, Tafuri A, Cognetti F, Anichini A, Zupi G, Milella M.

Neoplasia. 2009 Aug;11(8):720-31.

47.

ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype.

Soriani A, Zingoni A, Cerboni C, Iannitto ML, Ricciardi MR, Di Gialleonardo V, Cippitelli M, Fionda C, Petrucci MT, Guarini A, Foà R, Santoni A.

Blood. 2009 Apr 9;113(15):3503-11. doi: 10.1182/blood-2008-08-173914. Epub 2008 Dec 19.

PMID:
19098271
48.

BCR ligation induced by IgM stimulation results in gene expression and functional changes only in IgV H unmutated chronic lymphocytic leukemia (CLL) cells.

Guarini A, Chiaretti S, Tavolaro S, Maggio R, Peragine N, Citarella F, Ricciardi MR, Santangelo S, Marinelli M, De Propris MS, Messina M, Mauro FR, Del Giudice I, Foà R.

Blood. 2008 Aug 1;112(3):782-92. doi: 10.1182/blood-2007-12-127688. Epub 2008 May 16.

PMID:
18487510
49.

Characterization of ABL1 expression in adult T-cell acute lymphoblastic leukemia by oligonucleotide array analysis.

Chiaretti S, Tavolaro S, Ghia EM, Ariola C, Matteucci C, Elia L, Maggio R, Messina M, Ricciardi MR, Vitale A, Ritz J, Mecucci C, Guarini A, Foà R.

Haematologica. 2007 May;92(5):619-26.

50.

Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies.

Tortora G, Bianco R, Daniele G, Ciardiello F, McCubrey JA, Ricciardi MR, Ciuffreda L, Cognetti F, Tafuri A, Milella M.

Drug Resist Updat. 2007 Jun;10(3):81-100. Epub 2007 May 7. Review.

Supplemental Content

Loading ...
Support Center